9 Jan 2012 07:00
For immediate release | 9 January 2012 |
Futura Medical plc
("Futura" or "the Company")
Notification of Preliminary Results
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that it will issue its preliminary results for the year ended 31 December 2011 on Tuesday 13 March 2012.
A meeting for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan Communications, 107 Cheapside, London, EC2V 6DN.
For any further information please contact:
Futura Medical plc | |
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
Nomura Code Securities Limited | |
Phil Walker / Giles Balleny | Tel:+44 (0) 20 7776 1200 |
For media enquiries please contact: | |
Buchanan Communications | |
Mark Court / Jessica Fontaine | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)